AGENUS INC Foreign Currency Transaction Gain (Loss), before Tax
AGENUS INC (AGEN) reported Foreign Currency Transaction Gain (Loss), before Tax of -$200.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-03-16
- AGENUS INC foreign currency transaction gain (loss), before tax for fiscal 2025 was -$200.00K.
- AGENUS INC foreign currency transaction gain (loss), before tax for fiscal 2024 was -$29.00K.
- AGENUS INC foreign currency transaction gain (loss), before tax for fiscal 2023 was -$100.00K.
- AGENUS INC foreign currency transaction gain (loss), before tax for fiscal 2022 was -$400.00K, a 140.00% decline from fiscal 2021.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$200.00K 10-K · filed 2026-03-16 | |
| 2024-12-31 | -$29.00K 10-K · filed 2026-03-16 | |
| 2023-12-31 | -$100.00K 10-K · filed 2026-03-16 | |
| 2022-12-31 | -$400.00K 10-K · filed 2025-03-17 | |
| 2021-12-31 | $1.00M 10-K · filed 2024-03-14 | |
| 2020-12-31 | -$3.10M 10-K · filed 2023-03-16 | |
| 2019-12-31 | $100.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | -$2.20M 10-K · filed 2021-03-16 | |
| 2017-12-31 | $1.90M 10-K · filed 2020-03-16 | |
| 2016-12-31 | -$2.10M 10-K · filed 2019-03-18 | |
| 2015-12-31 | -$866.00K 10-K · filed 2018-03-16 | |
| 2014-12-31 | -$773.00K 10-K · filed 2017-03-16 | $773.00K 10-K · filed 2015-03-16 |
| 2013-12-31 | -$9.00K 10-K · filed 2016-03-15 | $9.00K 10-K · filed 2014-03-07 |
| 2012-12-31 | $11.00K 10-K · filed 2015-03-16 | |
| 2011-12-31 | $9.00K 10-K · filed 2014-03-07 | |
| 2010-12-31 | $45.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |